40
Participants
Start Date
December 4, 2015
Primary Completion Date
June 2, 2016
Study Completion Date
June 2, 2016
GSK3008348 Nebuliser solution
Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
Placebo Nebuliser solution
5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of \[18F\]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
GSK Investigational Site, London
Lead Sponsor
GlaxoSmithKline
INDUSTRY